JAMES B KUPLIC

Allopathic & Osteopathic Physicians|Internal Medicine SHEBOYGAN, WI NPI 1598733909

General Payments — all program years on this page

$195,932.93

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 103
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $32,241.60 across 17 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $31,920.0015
Travel and Lodging $321.602

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $32,241.6017

By program year

Program yearAmountRecords
2018 $23,280.0010
2019 $27,458.6022
2020 $25,480.0013
2021 $26,580.0013
2022 $41,131.6018
2023 $19,761.1310
2024 $32,241.6017

Records — PY2024 (17)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1137610223 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610227 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610231 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610235 Takeda Pharmaceuticals U.S.A., Inc. $1,680.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610238 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610242 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610246 Takeda Pharmaceuticals U.S.A., Inc. $1,680.00 05/22/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610249 Takeda Pharmaceuticals U.S.A., Inc. $140.70 05/22/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137610253 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610257 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610261 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610264 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610268 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610272 Takeda Pharmaceuticals U.S.A., Inc. $1,680.00 10/23/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610275 Takeda Pharmaceuticals U.S.A., Inc. $180.90 10/23/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137610279 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137610282 Takeda Pharmaceuticals U.S.A., Inc. $2,240.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.